Polyene microlide pre-liposomal powders |
| OF THE PREFERRED EMBODIMENT A stable powder suitable for the direct preparation of liposome-... |
|
Process for stabilizing liposomes |
| We claim: 1. A process for stabilizing liposomes comprising: a) first forming liposomes by ... |
|
cDNA encoding human phospholipase A.sub.2 polypeptide |
| OF THE INVENTION The present invention provides a novel intracellular human phospholipase A.sub.2 ... |
|
DNA encoding Bcl-2-associated proteins |
| The present invention relates to a nucleic acid molecule encoding a protein or a fragment thereof ... |
|
Hybridoma-producing NSO myeloma cell line |
| This invention is directed to NSO.sup.bcl-2 myeloma cells and to methods of producing said cells. T... |
|
Bax inhibitor proteins |
| The present invention provides substantially purified nucleic acid molecules encoding Bax inhibitor ... |
|
Phosphonomonoester nucleic acids, process for their preparation, and their use |
| What is claimed is: 1. A compound of formula I ##STR37## in which n is a number from zero to 100; A ... |
|
Oligonucleotide phosphate esters |
| OF THE PREFERRED EMBODIMENTS The present invention provides oligonucleotide analogs characterized ... |
|
Liposomes containing oligonucleotides |
| What we claim is: 1. A composition comprising cationic liposomes which consist essentially of ... |
|
|
Process of transfecting a cell with a polynucleotide mixed with an amphipathic compound and a DNA-binding protein
| Details |
Inventors: Wolff, Jon A.; Fritz, Jeffery; Budker, Vladimir; Hagstrom, James;
Assignee: Mirus Corporation (Madison, WI)
Primary Examiner: Ketter; James
Assistant Examiner: Brusca; John S.
Attorney, Agent or Firm: Johnson; Mark K.
The present invention provides a process of transfecting a cell with a polynucleotide mixed with one or more amphipathic compounds and an effective amount of a DNA-binding protein. Exemplary and preferred DNA-binding proteins are H1, H2A, and H2B. Exemplary and preferred amphipathic compounds are cationic amphipathic compounds. |
|
DETAILED DESCRIPTION The present invention includes a process of transfecting a polynucleotide into a cell for expression by associating a selected cell with an amphipathic compound, an effective amount of a polynucleotide-binding protein and a selected polynucleotide, in solution. The term "transfecting" means that a polynucleotide becomes associated with a selected cell. The polynucleotide can be on the membrane of the cell or inside the cytoplasm, nucleus, or other organelle of the cell. Other terms sometimes used interchangeably with transfecting include "delivering" or "transferring" a cell. The polynucleotide is delivered to the cell by associating the cell with one or more amphipathic compounds along with a polynucleotide-binding protein in a solution. The term "associating" means to put in communication with or to place in close proximity. The term "polynucleotide" is a term of art that refers to a string of at least two base-sugar-phosphate combinations. Nucleotides are the monomeric units of nucleic acid polymers. The term includes deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) in the from of an oligonucleotide, messenger RNA, anti-sense, plasmid DNA, parts of a plasmid DNA or genetic material derived from a virus. The selected cell can be a mammalian cell that is within the tissue in situ; the cell could also be removed and maintained in tissue culture in a primary, secondary, immortalized or transformed state. The amphipathic compound is a linear molecule with a polar first end causing that end to be hydrophilic (water-soluble); the second end is nonpolar and therefore hydrophobic (water-insoluble). The amphipathic compound can be cationic or incorporated into a liposome that is cationic or anionic. In one embodiment, the amphipathic compound is a non-natural polyamine. "Non-natural", in this application, means that, for example, the compound is not found in living matter. As contrasted with "natural" which in this application refers to a compound that is derived from animal or plant tissue directly or by recombinant means
|
| Related patents |
|
|
Compositions for the introduction of polyanionic materials into cells
The present invention provides compositions and methods which are useful for the introduction of polyanionic materials into cells. The compositions are mixtures of ...
|
|
|
Highly packed polycationic ammonium, sulfonium and phosphonium lipids
OF THE INVENTION The present invention provides novel, highly packed polycationic ammonium, sulfonium and phosphonium lipid compounds having unique properties and ...
|
|
|
Method for the liposomal delivery of nucleic acids
The present invention relates to a nucleic acid-liposome preparation, useful in delivery of nucleic acid-based materials to cells. The present invention further relates ...
|
|
|
Highly packed polycationic ammonium, sulfonium and phosphonium lipids
OF THE INVENTION The present invention provides novel, highly packed polycationic ammonium, sulfonium and phosphonium lipid compounds having unique properties and ...
|
|
|
N-[1, (1-1) -dialkyloxy] - and N- [1, (1-1) -dialkenyloxy]- alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
According to a first aspect of the invention, the compounds of this invention are illustrated by Formula (I): ##STR2## or an optical isomer thereof, wherein R.sup.1 and R...
|
|
|
Low stress conformal coatings of reliability without hermeticity for microelectromechanical system based multichip module encapsulation
The present invention overcomes the limitations of existing technology and addresses the needs therein by providing low stress conformal coatings. In one aspect of the ...
|
|
|
Nucleic acids encoding JTT-1 protein
What is claimed is: 1. An isolated nucleic acid comprising a nucleotide sequence that encodes a polypeptide comprising the amino acid sequence of SEQ ID NO:2. 2. The ...
|
|
|
Nucleic acids encoding calcitonin receptor and uses thereof
The Drawings The drawings are first described. FIGS. 1A and 1B are a composite of graphs depicting binding of porcine calcitonin to cells. FIG. 1A) Porcine calcitonin ...
|
|
|
Tricyclic macrolide antibacterial compounds
OF THE INVENTION Compounds of this invention, also referred to as "the compounds," comprise both fixed and variable moieties, which variable moieties are identified by ...
|
|
|
Gene encoding MNR2 and uses thereof
OF THE INVENTION The following standard abbreviations are used throughout the specification to indicate specific nucleotides: C=cytosine A=adenosine T=thymidine G=...
|
|
|